Corporate responsibility

View all stories
article thumbnail

Taking on Zaire ebolavirus

How science and innovation fuel our efforts to help combat a rare but potentially deadly disease

article thumbnail

The Wall Street Journal names Merck among top 10 best-managed companies 

We’re proud to be recognized for our strong performance and unwavering commitment to patients

article thumbnail

Safeguarding the environment through green chemistry

When a manufacturing process doesn’t meet our standards, we build an award-winning, planet-friendly one

article thumbnail

3 ways we support the LGBTQ+ community

How we stand by our commitment to allyship both within our company and in the world at large

article thumbnail

Helping protect health from birth to adulthood

Vaccination is one of the many ways you can help protect your loved ones against certain potentially serious diseases every day

article thumbnail

Merck recognized on Fortune’s 2022 Change the World list

Recognition highlights our continued focus on expanding access

article thumbnail

Our partnerships help make vaccines accessible worldwide

How our colleagues are collaborating with organizations to improve global vaccination rates

article thumbnail

Meet the inaugural Health Equity Catalyst Fund initiatives

Teams around the world will put new funding to good use helping address urgent global needs

article thumbnail

Accelerating global access

Our company is collaborating with a range of partners to enable access for patients around the world

article thumbnail

Merck publishes 2021/2022 Environmental, Social & Governance (ESG) Progress Report

Letter from our chief executive officer and president, Rob Davis

article thumbnail

How we’re prioritizing supply

Learn how our teams mobilized like never before to ensure we were ready to address a global need

article thumbnail

4 LGBTQ+ employees share stories of finding freedom to be themselves at work

Bringing your whole self to work allows you “to be happy not just in your personal life but also in your professional life"

article thumbnail

35 Years: The Mectizan® Donation Program

The Mectizan Donation Program is the longest-running, disease-specific drug donation program of its kind

article thumbnail

When the world needs us, together we rise to the challenge

Merck CEO & President Rob Davis shares news with colleagues about our investigational COVID-19 medicine

article thumbnail

Giving back: How our pro bono program drives positive change

Jennifer Zachary, Merck’s General Counsel, on how we can provide more legal services to those in need

article thumbnail

Creating a new world in Minecraft for students to explore

Periodic Odyssey

article thumbnail

7 things you probably didn’t know about Merck

From Thomas Edison to Meryl Streep, these interesting tidbits about our company may surprise you

article thumbnail

Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts

Grants Will Be Administered through the MECTIZAN® Donation Program and Will Support Precautionary Measures Required to Prevent the Spread of SARS-CoV-2 During Mass Drug Administration Programs for These Two Diseases Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the MECTIZAN® Donation Program (MDP), announced today a $500,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF). The funds are being provided by Merck and will be administered through an application process managed by the MDP, a public-private partnership that oversees elimination efforts of these two diseases. This funding will be offered in the form of grants to support the implementation of the World Health Organization’s (WHO’s) recommended precautionary measures to decrease the risk of the spread of SARS-CoV-2 during mass drug administration (MDA). This press release features multimedia.

article thumbnail

Merck Issues 2019/2020 Corporate Responsibility Report

Report Demonstrates Merck’s Approach to Long-Term Sustainability for Business and Society Merck (NYSE: MRK), known as MSD outside the United States and Canada, today issued its 2019/2020 Corporate Responsibility Report . The report highlights the company’s performance and progress in its four corporate responsibility priority areas of Access to Health, Employees, Environmental Sustainability and Ethics & Values. “The multiple challenges we face as a global community in 2020 reinforce more than ever the importance of operating responsibly, following our mission of saving and improving lives and delivering sustainable value for our business and society,” said Kenneth C. Frazier, Merck chairman and chief executive officer. “At Merck, we embrace our responsibility to be a force for good in the world – not only through our medicines and vaccines but also through our broader actions to address systemic inequities and to create an environment where all people are valued and respected.”

article thumbnail

Merck Publishes 2012 Global Corporate Responsibility Report

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today issued its 2012 global corporate responsibility report. The report, available at www.merckresponsibility.com , focuses on Merck's corporate responsibility activities, progress and performance during 2012 in four priority areas where the company is positioned to have a positive impact: Access to Health, Environmental Sustainability, Employees and Ethics and Transparency. Highlights from the 2012 report include: People reached through the company’s major responsibility programs and partnerships: 269 million Women in executive roles: 31 percent Global corporate giving: $1.7 billion Water recycled and reused during 2012: 3.3 billion gallons Reduced direct greenhouse gas emissions since 2009: Met 10 percent greenhouse gas reduction goal 3 years early Developing new partnerships to reduce maternal mortality through Merck for Mothers In addition, this year’s report provides information on the company’s commitment